Boeing upgraded, Under Armour downgraded: Wall Street's top analyst calls
Wall Street analysts issued multiple rating changes. Argus upgraded Boeing (BA) to Buy and set a $265 target; Truist upgraded Best Buy (BBY) to Buy with a $95 target; Argus upgraded Centene (CNC) to Buy with an $80 target. Other moves included UBS upgrading Jabil (JBL) to Buy, BofA downgrading AppLovin (APP) to Neutral, and Barclays downgrading Under Armour (UAA) to Underweight.
How this was made
The 30-second read
Why it matters
Net effect is mixed. Upgrades generally support upside sentiment where the thesis points to improving margins, demand signals, or AI/industrial growth cycles. Downgrades highlight growth durability, brand recovery delays, or earnings normalization risk.
Market read
For traders, the actionable element is the immediate sentiment shift from rating and price-target changes, especially where the thesis references near-term catalysts like upcoming Q2 reporting or specific KPI trends.
What to watch
Rating changes can be offset by upcoming earnings, guidance revisions, or broader sector rotations; traders should verify whether the cited leading indicators (e.g., credit card reads, risk score performance, ARR KPIs) are already reflected in consensus estimates.
Background
The article is a multi-stock roundup of Wall Street analyst rating changes, including several upgrades and multiple downgrades, each with a stated price target and a brief thesis.
Ticker impact
Argus upgraded Boeing to Buy from Hold and set a $265 price target, citing superior long-term prospects in commercial aerospace.
Mildly positive bias for BA around the upgrade headline; follow-through depends on broader market risk appetite.
The article provides a clear rating/target change and thesis, but no new operational datapoint (earnings, guidance, contract) is disclosed.
Barclays downgraded Under Armour to Underweight from Equal Weight, citing delayed brand recovery in a competitive athletic sector.
Downward pressure likely around the downgrade; magnitude depends on how crowded the prior consensus was.
The text includes a specific rating change and unchanged target, but no new sales/earnings datapoint is provided.
Truist upgraded Best Buy to Buy from Hold and raised its price target to $95, pointing to positive credit card reads for the Q2 report.
Moderately positive near-term bias into the Q2 report as traders price in stronger demand signals.
A concrete thesis is provided, but the article does not include the actual Q2 numbers or new guidance.
Argus upgraded Centene to Buy from Hold with an $80 price target, arguing Medicaid margins are bottoming and premiums should restore profitability.
Gradual positive bias as the market re-rates toward margin normalization.
The thesis is specific, but it is still forward-looking and not accompanied by new reported financial results.
UBS upgraded Jabil to Buy from Neutral with a $430 target, citing a multiyear growth cycle driven by AI investment and healthcare demand.
Mild-to-moderate positive bias, especially if investors are rotating into AI infrastructure supply chains.
The article is thesis-heavy but lacks any new Jabil-specific order, guidance, or contract disclosure.
Citi upgraded Agilon Health to Neutral from Sell and raised its price target to $115, citing better-than-expected risk score performance and cost trends.
Supportive for AGL as traders adjust probability-weighting toward stabilization.
The text cites measurable drivers (risk score performance, cost trends) but does not provide the underlying figures.
Citi upgraded Evolent Health to Buy from Neutral with a $6 price target, citing execution driving better risk score performance and cost trends.
Near-term positive bias, though likely limited without new reported metrics.
The article provides a rating/target change but no new quantitative disclosures.
BofA downgraded AppLovin to Neutral from Buy and cut its price target to $400, citing increased risks to its 30% long-term revenue growth forecast.
Negative bias for APP as traders reassess growth durability assumptions.
The thesis is specific (forecast risk), but the article does not cite new AppLovin results or guidance.
Market effects
Analyst calls skew toward commercial aerospace (BA), healthcare insurers (CNC, AGL, EVH), and AI infrastructure supply chain themes (JBL, CLS), while consumer discretionary and ad-tech growth durability concerns show up in UAA, ABNB, APP.
Air travel and consumer demand narratives are indirectly reflected via BA and ABNB, but no region-specific macro data is disclosed.
AI capex and industrial automation themes appear across multiple names, but the article does not provide cross-market macro catalysts.
Counterpoint
Because these are mostly analyst upgrades/downgrades without new company-reported datapoints, the market may already price in similar theses, limiting follow-through beyond the initial headline reaction.
Key entities
- companyBoeing
Upgraded to Buy from Hold by Argus with a $265 price target.
- companyUnder Armour
Downgraded to Underweight from Equal Weight by Barclays with an unchanged $5 price target.
- companyBest Buy
Upgraded to Buy from Hold by Truist with a raised $95 price target.
